BIOSYNEX (ALBIO.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:ALBIO - FR0011005933 - Common Stock
0.74 EUR
-0.01 (-0.8%)
Taking everything into account, ALBIO scores 2 out of 10 in our fundamental rating. ALBIO was compared to 67 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of ALBIO have multiple concerns. ALBIO has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year ALBIO has reported negative net income.
- ALBIO had a negative operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: ALBIO reported negative net income in multiple years.
- The reported operating cash flow has been mixed in the past 5 years: ALBIO reported negative operating cash flow in multiple years.
1.2 Ratios
- ALBIO has a Return On Assets of -47.50%. This is amonst the worse of the industry: ALBIO underperforms 85.07% of its industry peers.
- The Return On Equity of ALBIO (-160.22%) is worse than 83.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.5% | ||
| ROE | -160.22% | ||
| ROIC | N/A |
ROA(3y)-10.54%
ROA(5y)6.39%
ROE(3y)-24.67%
ROE(5y)7.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With a Gross Margin value of 58.82%, ALBIO perfoms like the industry average, outperforming 53.73% of the companies in the same industry.
- ALBIO's Gross Margin has been stable in the last couple of years.
- The Profit Margin and Operating Margin are not available for ALBIO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 58.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.7%
GM growth 5Y-0.09%
2. Health
2.1 Basic Checks
- ALBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for ALBIO remains at a similar level compared to 1 year ago.
- The number of shares outstanding for ALBIO has been increased compared to 5 years ago.
- Compared to 1 year ago, ALBIO has a worse debt to assets ratio.
2.2 Solvency
- ALBIO has an Altman-Z score of -0.73. This is a bad value and indicates that ALBIO is not financially healthy and even has some risk of bankruptcy.
- ALBIO's Altman-Z score of -0.73 is on the low side compared to the rest of the industry. ALBIO is outperformed by 76.12% of its industry peers.
- ALBIO has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.31, ALBIO is in the better half of the industry, outperforming 61.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.73 |
ROIC/WACCN/A
WACC5.71%
2.3 Liquidity
- ALBIO has a Current Ratio of 0.78. This is a bad value and indicates that ALBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
- ALBIO has a worse Current ratio (0.78) than 86.57% of its industry peers.
- A Quick Ratio of 0.45 indicates that ALBIO may have some problems paying its short term obligations.
- With a Quick ratio value of 0.45, ALBIO is not doing good in the industry: 86.57% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.78 | ||
| Quick Ratio | 0.45 |
3. Growth
3.1 Past
- ALBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -41.10%.
- ALBIO shows a decrease in Revenue. In the last year, the revenue decreased by -5.84%.
- The Revenue has been growing by 24.22% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-41.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-56.71%
Revenue 1Y (TTM)-5.84%
Revenue growth 3Y-35.81%
Revenue growth 5Y24.22%
Sales Q2Q%-5.91%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y475%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year15.05%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- ALBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Based on the Price/Forward Earnings ratio of 1.56, the valuation of ALBIO can be described as very cheap.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of ALBIO indicates a rather cheap valuation: ALBIO is cheaper than 98.51% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of ALBIO to the average of the S&P500 Index (24.32), we can say ALBIO is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1.56 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for ALBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:ALBIO (1/22/2026, 7:00:00 PM)
0.74
-0.01 (-0.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-17 2025-07-17
Earnings (Next)N/A N/A
Inst Owners0.39%
Inst Owner ChangeN/A
Ins Owners5.7%
Ins Owner ChangeN/A
Market Cap13.88M
Revenue(TTM)97.95M
Net Income(TTM)-70.99M
Analysts86.67
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1.56 | ||
| P/S | 0.14 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.31 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.31
EYN/A
EPS(NY)0.47
Fwd EY64.03%
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS5.22
BVpS2.36
TBVpS-1.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.5% | ||
| ROE | -160.22% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 58.82% | ||
| FCFM | N/A |
ROA(3y)-10.54%
ROA(5y)6.39%
ROE(3y)-24.67%
ROE(5y)7.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.7%
GM growth 5Y-0.09%
F-Score3
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 7.46% | ||
| Cap/Sales | 4.44% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.78 | ||
| Quick Ratio | 0.45 | ||
| Altman-Z | -0.73 |
F-Score3
WACC5.71%
ROIC/WACCN/A
Cap/Depr(3y)143.09%
Cap/Depr(5y)301.13%
Cap/Sales(3y)20.88%
Cap/Sales(5y)14.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-41.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-56.71%
EPS Next Y475%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-5.84%
Revenue growth 3Y-35.81%
Revenue growth 5Y24.22%
Sales Q2Q%-5.91%
Revenue Next Year15.05%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-72.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2216.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.71%
OCF growth 3YN/A
OCF growth 5YN/A
BIOSYNEX / ALBIO.PA FAQ
What is the fundamental rating for ALBIO stock?
ChartMill assigns a fundamental rating of 2 / 10 to ALBIO.PA.
Can you provide the valuation status for BIOSYNEX?
ChartMill assigns a valuation rating of 4 / 10 to BIOSYNEX (ALBIO.PA). This can be considered as Fairly Valued.
Can you provide the profitability details for BIOSYNEX?
BIOSYNEX (ALBIO.PA) has a profitability rating of 1 / 10.
What is the financial health of BIOSYNEX (ALBIO.PA) stock?
The financial health rating of BIOSYNEX (ALBIO.PA) is 1 / 10.